The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a novel HER2-targeted bispecific antibody for several types of cancers, an immunotherapy and PARP-inhibitor combination that may benefit specific tumor molecular subtypes, a comprehensive look at the efficacy of eligibility criteria...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president for Research. Gottlieb, an accomplished scientist and leader, will join MD Anderson in January to uphold and expand the institution’s research excellence.
In this role, Gottlieb will oversee laboratory science departments leading innovative discovery and translational research across a variety...
Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way...
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco...